Cell Genesys searches for a cure to prostate cancer

To read the complete article, please visit http://www.beaconequityresearch.com

Those who believe investing is simply a matter of evaluating the bottom line have obviously not examined the fundamentals of too many biotech corporations. Many emerging biotech firms are years away from actual production, and have horrific balance sheets. That does not mean potential investors should shy away from them altogether, but they really need to understand the story and how likely it is that the company will deliver the goods.

Just like panning for gold or drilling for oil, what these companies do offer is hope. In the case of Cell Genesys (NASDAQ: CEGE) it is the hope for a cure to prostate cancer, the second-deadliest form of cancer among men.

While CEGE focuses on a variety of different cancers and treatment options, it is the company’s GVAX immunotherapy for prostate cancer that is invoking memories of Louis Pasteur.

GVAX immunotherapy for prostate cancer is, in essence, a vaccine designed to enlist the body’s own immune system to ward off unhealthy, or cancerous, cells. And clinical trials seem to suggest that GVAX has at least landed some early punches in the fight.

To read the complete article, please visit http://www.beaconequityresearch.com

Beacon Equity Research Gainers are Broadcom Corp (Nasdaq: BRCM), Intel (Nasdaq: INTC), Sirius Satellite (Nasdaq: SIRI), Cisco Systems (Nasdaq: CSCO), Apple Inc (Nasdaq: AAPL), Yahoo Inc. (Nasdaq: YHOO), and Microsoft (Nasdaq: MSFT).

Beacon Equity Research Decliners are Comcast (Nasdaq: CMCSA), E Trade (Nasdaq: ETFC), Force Protection (Nasdaq: FPRT), Level 3 (Nasdaq: LVLT), Ebay (Nasdaq: EBAY), Applied Materials (Nasdaq: AMAT), and Palm Inc. (Nasdaq: PALM).

Contact Information

Jeff Bishop

Editor

Beacon Equity Research

Contact via E-mail